Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Vadim Koshkin
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Vadim Koshkin
I am a genitourinary medical oncologist and in this capacity I specialize in caring for patients with bladder, prostate, kidney and testicular cancers.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Taiho Oncology, Inc.
- ID
- NCT04601857
- Phase
- Phase 2 Transitional Cell Carcinoma Research Study
- Study Type
- Interventional
- Participants
- Expecting 46 study participants
- Last Updated